PolyPid (PYPD) Aktienübersicht
PolyPid Ltd. ist ein biopharmazeutisches Unternehmen, das mit seiner proprietären Polymer-Lipid-Verkapselungsmatrix (PLEX) zielgerichtete, lokal verabreichte Therapeutika mit verlängerter Wirkstofffreisetzung entwickelt, um ungedeckte medizinische Bedürfnisse zu erfüllen. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
PYPD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativePolyPid Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$4.38 |
| 52-Wochen-Hoch | US$5.12 |
| 52-Wochen-Tief | US$2.44 |
| Beta | 1.41 |
| 1 Monat Veränderung | 1.62% |
| 3 Monate Veränderung | -6.41% |
| 1 Jahr Veränderung | 53.68% |
| 3 Jahre Veränderung | -59.44% |
| 5 Jahre Veränderung | -98.40% |
| Veränderung seit IPO | -99.23% |
Aktuelle Nachrichten und Updates
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?
Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?Recent updates
Long Regulatory And Commercial Risks Around Lead Therapy Could Eventually Reward Patient Holders
Catalysts About PolyPid PolyPid is a biopharmaceutical company developing locally and systemically delivered, long acting therapies based on its proprietary drug delivery technology, with D PLEX100 for prevention of surgical site infections as its lead program. What are the underlying business or industry changes driving this perspective?Regulatory Tailwinds And Extended Release Platform Will Shape A Stronger Long Term Outlook
Catalysts About PolyPid PolyPid is a biopharmaceutical company focused on extended release drug delivery products such as D-PLEX100 for prevention of surgical site infections and longer acting metabolic therapies using its Kynatrix technology. What are the underlying business or industry changes driving this perspective?
Long Acting Drug Delivery And Metabolic Health Pipeline Will Transform Future Prospects
Catalysts About PolyPid PolyPid is a clinical stage biopharmaceutical company focused on long acting drug delivery products such as D PLEX100 for prevention of surgical site infections and a GLP 1 receptor agonist program for metabolic disease. What are the underlying business or industry changes driving this perspective?Is PolyPid (NASDAQ:PYPD) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...PolyPid set to cut 20% jobs
PolyPid (NASDAQ:PYPD) announced on Thursday a cost reduction plan, including a 20% job cut across all departments as it expects the actions to extend tits cash runway into Q3 2023. The company expects to discuss regulatory pathway for D-PLEX100 for prevention of surgical site infections in abdominal surgery with U.S. and EU regulatory authorities in Q1 2023. As of February 28, the company had 78 full-time employees.PolyPid's surgical site infections treatment eligible for marketing nod submission in EU
PolyPid (NASDAQ:PYPD) on Wednesday said it had got confirmation from Europe's drug regulator that its D-PLEX100 product candidate for the treatment of surgical site infections was eligible to be submitted for a marketing authorization. The company said the product candidate was eligible for the European Medicines Agency's (EMA) centralized procedure under the therapeutic innovation criteria. "The centralized procedure allows the submission of a single marketing application to the EMA that, if approved, enables the product to be marketed in all EU member states as well as in Iceland, Liechtenstein and Norway," PYPD said in a statement. The company is currently evaluating its recently concluded phase 3 trial which evaluated D-PLEX100 for the prevention of surgical site infections in abdominal surgery. PYPD said it intends to discuss the data from the late-stage trial and potential next steps with U.S. and EU regulators in Q1 2023. PolyPid (PYPD) stock +1.2% to $1.10 in morning trading.PolyPid sheds 75% as lead candidate fails in Phase 3 trial for post-surgical infections
PolyPid Ltd. (NASDAQ:PYPD) dropped ~75% in value in the pre-market trading Friday after the Israeli company announced that its lead candidate D-PLEX100 did not meet the main goal in a Phase 3 trial for the prevention of surgical site infections ((SSIs)) in abdominal surgery. The SHIELD I was designed to evaluate the joint administration of D-PLEX100 standard of care (SoC) against SoC alone arm in 970 patients out of whom 488 were part of the D-PLEX100 treatment arm and 489 were in the control arm. The trial did not achieve the primary endpoint of reduction in surgical site infections and mortality, the company said noting that in the Intent to Treat (ITT) population, D-PLEX100 and SoC (n=485) led to 23% decrease in SSIs and mortality compared to SoC alone (n=489) (p=0.1520).PolyPid GAAP EPS of -$1.23 misses by $0.60
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$1.23 misses by $0.60. As of June 30, 2022, the Company had cash and cash equivalents and deposits in the amount of $23.8 million, not including the second tranche of $2.5 million from the Kreos Capital VI (Expert Fund) LP (“Kreos”) loan, which was drawn in July 2022.PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) signed an exclusive licensing agreement for its lead drug candidate D-PLEX100 in Europe with U.K.-based Advanz Pharma (OTCPK:CXRXF). D-PLEX100 is used for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries, in Europe. Under the agreement, PolyPid will receive $2.6M upfront and development-related milestones of up to $20.9M. Upon commercialization, PolyPid will receive up to $89M in sales-related milestones, the company said in an Aug. 3 press release. In addition, PolyPid will also supply D-PLEX100 to Advanz for a transfer price and will be entitled to royalties on net sales in double-digit percentages of up to mid-twenties. "Advanz Pharma's expertise in marketing hospital-based therapies, combined with its significant resources and relationships in the region, will prove invaluable in expanding access to D-PLEX100 and delivering this much-needed therapy, if approved, to patients," said PolyPid's CEO Dikla Czaczkes Akselbrad.PolyPid: Strong Pipeline, Close Catalysts
PolyPid develops a platform technology to provide locally controlled and continuous delivery of medications. Lead product candidate D-PLEX100 is investigated for the prevention of sternal and abdominal surgical site infections serving a huge market. Meaningful interim results and topline data from pivotal Phase 3 SHIELD I clinical trial will soon be published. Measured in terms of the clinical benefit of D‑PLEX100 and its estimated market size, PolyPid is clearly undervalued at present in our view.Will PolyPid (NASDAQ:PYPD) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Watching PolyPid's (NASDAQ:PYPD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Aktionärsrenditen
| PYPD | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -2.2% | -1.9% | 2.2% |
| 1Y | 53.7% | 33.5% | 31.1% |
Rendite im Vergleich zur Industrie: PYPD übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 33.5 erzielte.
Rendite vs. Markt: PYPD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 31.1 erzielte.
Preisvolatilität
| PYPD volatility | |
|---|---|
| PYPD Average Weekly Movement | 5.4% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: PYPD hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: PYPDDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2008 | 72 | Dikla Czaczkes Akselbrad | www.polypid.com |
PolyPid Ltd. ist ein biopharmazeutisches Unternehmen, das mit seiner proprietären Polymer-Lipid-Verkapselungsmatrix (PLEX) gezielte, lokal verabreichte Therapeutika mit verlängerter Wirkstofffreisetzung entwickelt, um ungedeckte medizinische Bedürfnisse zu erfüllen. Der führende Produktkandidat ist D-PLEX100, der sich in einer entscheidenden Phase-3-Bestätigungsstudie zur Vorbeugung von Infektionen an der Operationsstelle (SSI) bei Patienten befindet, die sich einer abdominalen kolorektalen Operation mit großen Einschnitten unterziehen. Das Unternehmen entwickelt außerdem OncoPLEX, das sich in der präklinischen Phase für die Behandlung von Krebs innerhalb des Tumors befindet.
PolyPid Ltd.'s Grundlagenzusammenfassung
| PYPD grundlegende Statistiken | |
|---|---|
| Marktanteil | US$83.58m |
| Gewinn(TTM) | -US$34.17m |
| Umsatz(TTM) | n/a |
Ist PYPD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PYPD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$0 |
| Kosten der Einnahmen | US$0 |
| Bruttogewinn | US$0 |
| Sonstige Ausgaben | US$34.17m |
| Gewinn | -US$34.17m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
May 13, 2026
| Gewinn per Aktie (EPS) | -1.79 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 9.0% |
Wie hat sich PYPD auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/11 20:11 |
| Aktienkurs zum Tagesende | 2026/05/08 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
PolyPid Ltd. wird von 8 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |